Browse
Browse
Home
People
Organizations
Research
Events
Capability Map
UAB17127:A phase Ib trial of fulvestrant, palbociclib (CDK4/6 inhibitor) and erdafitinib (JNJ- 42756493, pan-FGFR tyrosine kinase inhibitor) in ER+/HER2–/FGFR-amplified metastatic breast cancer (MBC)
Grant
Overview
Affiliation
Overview
Awarded By
VANDERBILT UNIVERSITY
Total Award Amount
0.00
Direct Costs
0.00
Sponsor Award Id
Affiliation
Contributor
Erica Stringer-Reasor M.D.
Investigator
Gabrielle Rocque M.D.
Investigator